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Abstract
Objectives Odontogenic keratocyst (OKC) presents considerable variation in aggressiveness and propensity for recurrence, yet
hitherto, no explicit clinicopathological features have been determined to clearly demonstrate the potential for relapse. This
retrospective study aims to investigate the prognostic relevance of various clinicopathological features as well as
immunoexpression of COX-2, bcl-2, PCNA, and p53 in sporadic OKC.
Materials and methods Among 41 patients with OKC treated by enucleation, the frequency of recurrence for various clinico-
pathological features as well as immunoexpression for COX-2, bcl-2, PCNA, and p53 was evaluated.
Results The mean follow-up was 8.49 years, and recurrences were ascertained in 29.27% of cases. We found significant
differences between recurrent and non-recurrent cysts in terms of multilocularity (P = 0.029), cortical perforation (P = 0.001),
and lesion size (P < 0.001). Hazard risk for the recurrence was 3.362 (95% CI 1.066–10.598) for multilocular cysts, 7.801 (95%
CI 2.1–28.985) for evidence of cortical perforation, and 1.004 (1.002–1.006) for 1 mm2 of lesion size on panoramic radiographs.
We also found that immunoexpression of PCNA significantly correlates with the radiographic evidence of cortical perforation
(P = 0.048) and that there is significant positive correlation between expression of COX-2 and bcl-2 (P = 0.001) as well as
significant negative correlation between immunoexpression of COX-2 and age (P = 0.002). None of the other analyzed factors
were associated with the recurrence.
Conclusions Larger size, multilocularity, and cortical perforation in sporadic OKC may be correlated with the relapse.
Clinical relevance Immunohistochemical analyses of COX-2, bcl-2, PCNA, and p53 lack prognostic utility in sporadic OKC.
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Introduction
The keratocystic odontogenic tumor (KCOT) was defined by
the World Health Organization (WHO) in 2005 as a benign,
intraosseous tumor of odontogenic origin, with characteristic
lining of parakeratinized stratified squamous epithelium and a
potential for aggressive, infiltrative behavior [1]. It was be-
lieved that this term better reflected the neoplastic nature of
this lesion in comparison with the previous term of
odontogenic keratocyst (OKC). However, only recently,
WHO decided to move KCOT back into the cyst category as
OKC [2]. Mutations in the PTCH gene which were the main
evidence for 2005 classification of the lesion into a group of
odontogenic tumors are currently believed not to be KCOT-
specific, and there are documented cases of spontaneous
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regression of the lesion following only its partial removal
(decompression or marsupialization) which contradicts the
main concept of autonomy of neoplasm continuing to grow
after the stimulus which produced it is removed [3].
OKC is a quite common clinical finding as it accounts for
10–20% of odontogenic cysts and is the third most common
cyst of the jaws [2]. A number of treatment modalities have
been recommended for OKC, including simple enucleation,
enucleation followed by Carnoy’s solution application, and
decompression as being the most commonly employed [4].
Several systematic reviews and meta-analyses have been pro-
duced to establish which method results in the lowest recur-
rence rate; however, their conclusions are ambiguous and the
golden standard treatment for OKC remains hotly debated
[5–7]. Among reasons for this, the considerable variation in
aggressiveness and propensity for recurrence of OKC is wide-
ly acknowledged [6, 8], and hitherto, no explicit clinical and
radiological features have been determined to clearly demon-
strate the potential for the aggressive growth and relapse of the
lesion. Hence, the researchers have tried to elucidate the rela-
tionship between the expression of various molecular markers
and the biological potential of OKC. Some studies have
shown that the local aggressiveness of OKC and its propensity
for recurrence may be consistent with the expression of sev-
eral markers of epithelial cell proliferation and apoptosis, in-
cluding Ki-67 [8], bcl-2 [9], cyclin D1 [9], p53 [9], and PCNA
[9, 10].
Studies have demonstrated that cyclooxygenase-2 (COX-
2) levels are elevated in various tumors, particularly those
involving the gastrointestinal tract, lung, skin, urinary bladder,
and prostate as well as head and neck [11]. The regulation of
COX-2 expression is crucial for prostaglandin E2 (PGE2) syn-
thesis, and its upregulation may increase the synthesis of pros-
taglandins (PGs), thus promoting cell proliferation and angio-
genesis, and inhibiting immunosurveillance [12]. Recent stud-
ies revealed that COX-2 is also overexpressed in OKC, thus
suggesting that it may be an important marker involved in the
biologic behavior of the OKC [12, 13]. It has also been found
that COX-2 expression in OKC is significantly decreased fol-
lowing decompression [13] and that its expression is not cor-
related with clinical features of the lesion [12]. However,
prognostic significance of immunopositivity of COX-2 in
OKC has not hitherto been examined.
Overexpression of the COX-2 gene inhibits apoptosis and
enhances invasiveness which has been attributed, to some
extent, to increased level of antiapoptotic protein B cell lym-
phoma 2 (bcl-2) [11] which, in contrast to radicular and
dentigerous cysts, is upregulated in OKC [14]. Apart from
apoptosis-related factors involved in development of OKC,
proliferative activity of its lining epithelium has been the sub-
ject of various investigations. Such studies concluded that
proliferative activity of OKC epithelium is significantly
higher than in other types of odontogenic cysts, as shown by
immunopositivity of several markers, including proliferating
cell nuclear antigen (PCNA) [10] and p53 [15]. p53 status is
associated with COX-2 and PCNA expression [15] as well as
some clinical features of OKC, such as recurrence and asso-
ciation with nevoid basal cell carcinoma syndrome (NBCCS)
[16].
Based on the aforementioned findings, the primary objec-
tive of this study was therefore to identify the association
between recurrence-free survival and protein expression of
COX-2, bcl-2, PCNA, and p53 by immunohistochemistry so
as to find a prognostic marker in OKC. The secondary objec-
tive was to elucidate any relationship between clinicopatho-
logical findings and recurrence as well as immunoexpression
of COX-2, bcl-2, PCNA, and p53.
Materials and methods
Sixty-five cases diagnosed with OKC or KCOT by histopa-
thology and confirming to 2017 WHO criteria of OKC were
selected for this retrospective study. Patients were treated be-
tween 1997 and 2015 in two units of oral surgery in Poland
(Department of Oral Surgery at the Medical College of the
Jagiellonian University in Krakow and Academic Center of
Dentistry and SpecializedMedicine in Bytom). All cases were
treated by simple enucleation. This method refers to surgically
shelling the cyst out of the bone to remove the entire lesion
without leaving any macroscopic remnants [6, 17]. Following
enucleation, no bone regeneration graft materials were ap-
plied. Cases treated by means of enucleation with any adjunct
procedure (e.g., peripheral ostectomy, Carnoy’s solution, liq-
uid nitrogen) or method using partial removal of the cyst lin-
ing (marsupialization or decompression) were not included in
this analysis. The surgical technique used was standardized
among surgeons performing enucleation. Among 65 subjects,
12 cases were lost to follow-up after 6 months of surgical
treatment and were thus excluded. Twelve subjects with
NBCCS-associated OKCs were also excluded from the anal-
ysis. A total of 41 subjects treated for OKC were finally
reviewed. Ethical approvals were obtained from Bioethical
Committee of the Jagiellonian University (KBET/58/B/
2012) and Bioethical Committee of the Medical University
of Silesia (KNW/0022/KB/275/16).
Panoramic and occlusal radiographs were taken at the time
of diagnosis and at follow-up visits (quarterly for the first post-
operative year and semiannually from the subsequent year). In
most cases, CT or CBCT scans were also performed. During
follow-up period, gradual bone regeneration has been radio-
logically observed. At follow-up appointments, all patients
were evaluated for any symptoms of recurrence (e.g., clinical
bone expansion and/or radiological detection of suspicious
radiolucent zone in the area of previously enucleated cyst).
The relapse period was defined from the time of surgery to
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the time of detection of recurrence. Each recurrent lesion was
histopathologically confirmed to meet the WHO microscopic
criteria of OKC [2].
The following clinicoradiological data were retrieved: age,
gender, observation period and evidence of relapse, cyst loca-
tion, size of entire cystic area in radiographs (calculated by
multiplying the major and minor axes on panoramic radio-
graphs), tumor variant (uni- or multilocular), and radiological
evidence of cortical perforation (destruction of cortex by a
lytic process) which has been described as a possible imaging
feature of OKC [1]. Histopathological characteristics analyzed
were as follows: existence of daughter cysts, presence and
intensity of inflammation, and epithelial dysplasia. Cyst loca-
tion was divided into the following anatomical sites: anterior
maxilla, posterior maxilla, anterior mandible, and posterior
mandible. The boundary line between anterior and posterior
maxilla/mandible was the posterior surface of the second pre-
molar. Observation periods and any evidence of relapse were
also retrieved.
Formalin-fixed, parafin-embedded archival blocks were
sectioned and stained by hematoxylin-eosin (H&E). Slides
with 5-μm-thick tissue sections were used to confirm a diag-
nosis of OKC and to evaluate histopathological characteristics
(existence of daughter cysts, presence and intensity of inflam-
mation, and epithelial dysplasia) using a light microscope. The
intensity of inflammation was measured by counting inflam-
matory cells and stratified by using 4-grade scoring system
according to Kuroyanagi et al. [8]: grade 0—no inflammation,
grade 1—less than 15 cells, grade 2—15–50 cells, and grade
3—over 50 cells in 10 high-power fields (HPFs).
For immunohistochemical analysis, paraffin-embedded
3-μm-thick tissue sections were used. After antigen retrieval,
sections were blocked by incubation with 3% H2O2 and the
next slides were incubated with following antibodies:
& Rabbit monoclonal COX-2 (SP21, Cell Marque, Rocklin,
CA, USA; 1:200) room temp., 45 min;
& Rabbit monoclonal bcl-2 (E17, Cell Marque, Rocklin,
CA, USA; 1:300) 4 °C, overnight;
& Mouse monoclonal p53 (DO7, Cell Marque, Rocklin, CA,
USA; 1:100) room temp., 50 min; and
& Rabbit polyclonal PCNA (RB-9055-P0, Thermo
Scientific, Fremont, CA, USA; 1:700) room temp.,
30 min.
Subsequently, sections were treated with Primary Antibody
Amplifier Quanto followed by HRP Polymer Quanto
(Thermo Scientific, Fremont, CA, USA). The slides were then
stained with 3-3′-diaminobenzidine DAB Quanto (Thermo
Scientific, Fremont, CA, USA). Eventually, tissue sections
were counterstained with hematoxylin, dehydrated, and cov-
ered with coverslips for further analysis. Tonsil was used as
positive control for bcl-2, p53, and PCNA. For negative
control, sections were treated as above but without the primary
antibody. Cellular staining patterns in the epithelium of OKC
were cytoplasmic for COX-2, membranous-cytoplasmic for
bcl-2, or nuclear for p53 and PCNA.
Semiquantitative assessment of COX-2 and bcl-2 using 4-
grade scoring system was used: grade 0—negative reaction
(no staining cells), grade 1—staining of 1–25% cells, grade
2—staining of 26–50% cells, and grade 3—more than 50% of
staining cells in the epithelium. For PCNA and p53, quantita-
tive assessment was applied. The number of positive staining
cells was evaluated per 1000 epithelial cells and expressed in
percentage. All histopathological and immunohistochemical
evaluations were made by board-certified specialist in
pathomorphology (B.D.).
All clinicopathological and immunohistochemical features
were evaluated against the frequency of recurrence. Results
were reported as mean (± SD) or median (range) where ap-
propriate. Differences in clinicoradiological and pathological
data were analyzed using Fisher’s exact test, Student’s t test,
and Mann-Whitney test where appropriate. Cox proportional
hazard model for time-dependent variables was implemented
to evaluate hazard ratio and 95% confidence intervals (CI) as
estimates of hazard risk (HR) for a recurrence potential.
Associations between clinicoradiological and histopathologi-
cal features and immunoexpression of COX-2, bcl-2, PCNA,
and p53 were determined by Spearman correlation analysis. P
values less than 0.05 were considered significant. All analyses
were performed using the R Project for Statistical Computing.
Results
The mean age of patients at the time of surgery was 40.24 (±
18.3) years, and the mean follow-up was 8.49 (± 4.34) years.
Recurrences were ascertained in 12 (29.27%) cases. The mean
recurrence period was 3.92 (± 2.61) years. The mean age of
patients with non-recurrent cysts at the time of surgery was
40.76 (± 17.2) years, and of those with recurrent cysts was 39
(± 21.52) years (P = 0.784; Student’s t test). The age of a pa-
tient at the time of diagnosis was not associated with recur-
rence [HR 0.997, 95% CI 0.966–1.03 (P = 0.855)].
Clinicoradiological and histopathological characteristics of
the cases are presented in Table 1. The median size of recur-
rent cysts was 782.5 (range 673.5–978.5) mm2, and of non-
recurrent cysts was 375 (330–420) mm2 (P < 0.001; Mann-
Whitney test). The size of lesion was significantly associated
with cyst relapse [HR 1.004, 95% CI 1.002–1.006
(P < 0.001)] by the Cox proportional hazard model. We also
found that radiological evidence of multilocularity as well as
radiological evidence of cortical perforation was significantly
associated with recurrence of OKC (Table 1). None of the
other clinicoradiological findings were significantly associat-
ed with relapse of OKC (Table 1).
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According to the WHO definition of OKC [2], every
case analyzed in this study was lined with parakeratinized
stratified squamous epithelium. Epithelial dysplasia was a
very rare finding. Only low-grade squamous epithelial
dysplasia was diagnosed in one non-recurrent and in one
recurrent cysts. Inflammation was more common in recur-
rent (50%) than in non-recurrent (41.4%) lesions.
Additionally, among the recurrent cases, the strong inten-
sity of inflammation (grade 3) was observed twice as of-
ten as in non-recurrent lesions. In turn, the presence of
daughter cysts was comparable between recurrent and
non-recurrent OKCs (25 and 24.1%, respectively). None
of the analyzed histopathological findings were signifi-
cantly associated with recurrence (Table 1).
Details of immunoexpression of individual molecules are
given in Figs. 1, 2, 3, and 4. We found no significant differ-
ences in the expression of any marker between recurrent and
non-recurrent OKCs (Tables 2 and 3). Complete characteris-
tics of the recurrent cases are presented in Table 4.
Spearman correlation analysis showed that expression of
COX-2 was negatively correlated with age (r = − 0.461; P =
0.002) and that expression of PCNAwas positively correlated
with radiological evidence of cortical perforation (r = 0.311;
P = 0.048). Furthermore, the positive correlation between ex-
pression of COX-2 and bcl-2 was revealed (r = 0.505; P =
0.001). No other significant correlations between expression
of individual proteins and clinicoradiological and histopatho-
logical features of OKC were discovered.
Table 1 Clinicoradiological and histopathological characteristics of the cases with hazard risks for recurrence of OKC
Recurrent cysts
(n = 12)
Non-recurrent cysts
(n = 29)
Total (n = 41) P value (Fisher’s exact test) Cox proportional hazard model
HR (95% CI) P value
Gender
Male 9 (75.0%) 12 (41.4%) 21 (51.2%) 0.085 1.00
Female 3 (25.0%) 17 (58.6%) 20 (48.8%) 0.311 (0.084–1.15) 0.08
Cyst location
Posterior mandible 5 (41.7%) 15 (51.7%) 20 (48.8%) 0.394 1.00
Anterior mandible 4 (33.3%) 5 (17.2%) 9 (22.0%) 2.162 (0.578–8.081) 0.252
Anterior maxilla 3 (25.0%) 5 (17.2%) 8 (19.5%) 1.645 (0.392–6.898) 0.496
Posterior maxilla 0 (0.0%) 4 (13.8%) 4 (9.75%) NR
Cyst variant
Unilocular 5 (41.7%) 23 (79.3%) 28 (68.3%) 0.029* 1.00
Multilocular 7 (58.3%) 6 (20.7%) 13 (31.7%) 3.362 (1.066–10.598) 0.039*
Cortical perforation
Negative 3 (25.0%) 24 (82.8%) 27 (65.8%) 0.001* 1.00
Positive 9 (75.0%) 5 (17.2%) 14 (34.2%) 7.801 (2.1–28.985) 0.002*
Inflammatory score
Grade 0 6 (50.0%) 12 (41.4%) 18 (44.0%) 0.821 1.00
Grade 1 3 (25.0%) 11 (37.9%) 14 (34.2%) 0.572 (0.143–2.291) 0.43
Grade 2 2 (16.7%) 5 (17.2%) 7 (17.1%) 0.831 (0.168–4.122) 0.821
Grade 3 1 (8.3%) 1 (3.45%) 2 (4.9%) 2.062 (0.245–17.345) 0.505
Daughter cysts
Negative 9 (75.0%) 22 (75.9%) 31 (75.6%) 0.864 1.00
Positive 3 (25.0%) 7 (24.1%) 10 (24.4%) 1.26 (0.34–4.667) 0.729
Epithelial dysplasia
Negative 11 (91.7%) 28 (96.6%) 39 (95.1%) 0.505 1.00
Positive 1 (8.3%) 1 (3.4%) 2 (4.9%) 1.518 (0.196–11.777) 0.69
Asterisks denote statistical significance
NR, no recurrence; HR, hazard ratio; CI, confidence interval
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Discussion
OKC is a lesion of ambiguous nature. Some OKCs do not recur
after marsupialization or other conservative approaches, while
some show aggressive behavior and tendency to relapse despite
more radical treatment [18]. Several studies have analyzed
clinicoradiological features and immunohistochemical expres-
sion of various indicators of proliferation and apoptosis in OKC
to discover prognostic markers [9, 10, 12, 19], but only a few
attempted to employ the time-dependent analysis for determin-
ing its potential for recurrence after surgery [8]. The present
study retrieved the clinical, radiological, and histopathological
data of 41 sporadic cases of OKC and, together with their im-
munohistochemical expression of COX-2, bcl-2, PCNA, and
p53, endeavored to correlate themwith the potential for relapse.
Among radiological findings investigated in the current anal-
ysis, multilocularity and cyst size were significantly related to
recurrence. These results are in line with observations by other
authors [9, 19, 20]. It has been demonstrated that smaller OKCs
are usually unilocular, whereas larger lesions tend to be
multilocular [21, 22]. Most probably, this is the reason why
larger and multilocular OKCs are more prone to recur than
smaller and unilocular lesions which are easier to enucleate in
one piece. Many authors pointed out that recurrence of OKC
may be related to inadequate treatment as multilocular and large
lesions are difficult to access and the fragments are easily
overlooked in the course of surgical procedure [19, 20].
However, in some reports, size and multilocularity were not
associated with recurrence of OKC [8, 23].
To the best of our knowledge, in none of the previous reports,
radiological presence of cortical perforation was examined as a
potential prognostic factor in OKC. This imaging feature is oc-
casionally observed in OKC [1] and may be a manifestation of
destructive clinical behavior of a lesion. Hence, it is more often
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Fig. 1 COX-2—cytoplasmic
brown staining in the superficial
layer (asterisks) of the epithelial
lining of OKC [×60]
Fig. 2 bcl-2—membranous-
cytoplasmic brown staining in the
basal (arrows) and suprabasal
(asterisks) layers of the epithelial
lining of OKC [× 60]
discovered in aggressive odontogenic tumors like ameloblastoma
than in benign odontogenic cysts. Although neoplastic nature of
OKC is currently not supported [2, 3], a few studies demonstrat-
ed its potential to infiltrate through the medullary spaces and
erode cortical bone which is similar to ameloblastoma [24, 25].
Cortical perforation may indicate the involvement of adjacent
soft tissues which, in turn, may lead to incomplete removal of
the cyst and subsequent relapse. In the current study, cortical
perforation has been identified as a very significant prognostic
factor as its presence in radiologic examination is associated with
7.8 times higher risk of recurrence. Hence, conservative treat-
ment (which was implemented in our study) may be insufficient
to remove the entire lining of OKC and the remaining tissue may
lead to recurrence. Consequently, some authors postulated that to
prevent relapse, the overlying attached mucosa may need to be
excised in conjunction with enucleation or even partial bone
resection could be applied in some more extensive cases [7].
In the current study, the site of involvement was not related
to recurrence and this finding is consistent with that of Yagyuu
et al. [19] and with that of Naruse et al. [26]. Likewise, results
of thorough analysis of 6427 OKC cases performed by
Chrcanovic and Gomez [20] indicated that there are no appar-
ent differences in the recurrence rates between lesions located
in the maxilla and in the mandible. Interestingly, Myoung
et al. [27] found no significant difference between recurrence
rates of OKC occurring in the maxilla and occurring in the
mandible, but in further detailed investigation of recurrence
rates of six subdivided jaw regions, they revealed that man-
dibular molar region was markedly more prone to relapse.
They suggested that the differences in recurrence rate might
be related to the area’s surgical accessibility [27]. Indeed, the
posterior mandibular region as well as mandible ramus has
been recognized to present the difficulty of complete cyst
removal [28].
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Fig. 3 PCNA—nuclear brown
staining (arrows) in the epithelial
lining of OKC [× 60]
Fig. 4 p53—nuclear brown
staining (arrows) in the epithelial
lining of OKC [× 60]
OKC may show small daughter (satellite) cysts [2], and ac-
cording to Pavelić et al. [29], these are present in 20.5% cases of
OKC. Correspondingly, in the current series, daughter cysts
were found in 24.4% of cases. Their occurrence is more com-
mon in NBCCS-associated cases of OKC [2]. Some authors
demonstrated that the presence of daughter cysts may be related
to the recurrence of OKC [27]; nonetheless, we did not find
such a correlation. Similar to our results, the presence of daugh-
ter cysts was also not associatedwith recurrence rates of OKC in
the series investigated by Kuroyanagi et al. [8] and Naruse et al.
[26]. Previous studies reported that the presence of daughter
cysts is significantly associated with a high frequency of allelic
loss in tumor suppressor genes, thus suggesting its neoplastic
nature [16]. Currently, however, experts do not support the neo-
plastic background of OKC development [2, 3].
Many attempts have been made to elucidate biological be-
havior of OKC, and investigations have tried to identify var-
ious molecular markers as potential factors indicating propen-
sity of OKC towards relapse. It has been suggested that COX-
2 may contribute to the biological profile of OKC, playing a
role in the biological regulation of its epithelial lining [30].
Wang et al. [13] demonstrated that COX-2 is at least partially
involved in the mechanism of progression of OKC and that its
immunoexpression significantly decreases after decompres-
sion, one of the surgical options of treatment that results in
shrinking of the cyst size. COX-2 levels have been found to be
elevated in majority of tumors, and its prognostic significance
has been demonstrated in several of them, including head and
neck cancer [31]. Although in the current study
immunopositivity of COX-2 has been demonstrated in major-
ity of cases, we did not find that the level of its expression has
any prognostic significance in OKC. Other studies elucidating
association between COX-2 expression and recurrence in
OKC are scarce but produced the same conclusions [12].
Mendes et al. [12] suggested that lack of association between
the expression of COX-2 and clinical features shows that the
pathogenic mechanism involved in OKC is not Bclinical-
related^ and it unveils an intrinsic characteristic of OKC that
bears no association either with its syndromic or primary na-
ture, thus substantiating previous molecular studies establish-
ing the neoplastic nature of this lesion [12, 32–34].
COX-2 is known to increase the level of bcl-2 which, in turn,
suppresses apoptosis by preventing activation of caspases re-
sponsible for cell death [11, 35]. Studies on bcl-2 expression
in OKC are few in number and most of them are confined to
primary lesions. Vered et al. [36] demonstrated that bcl-2 expres-
sion in primary sporadic and syndromic OKCs was similar to
solid ameloblastoma but significantly higher in comparisonwith
clinically benign radicular, dentigerous, and orthokeratinized
odontogenic cysts. These observations are consistent with other
authors [14] andmay suggest that biological behavior of OKC is
different from other common jaw cysts. It has also been dem-
onstrated that bcl-2 immunopositvity is significantly higher in
syndromic OKCs than in their sporadic counterparts [37]. In the
Table 2 Immunohistochemical expression of COX-2 and bcl-2 in the epithelial component of OKCs with hazard risks for recurrence
Recurrent cysts
(n = 12)
Non-recurrent cysts
(n = 29)
P value (Fisher’s exact test) Cox proportional hazard model
HR (95% CI) P value
COX-2 0% positive cells 1 (8.3%) 3 (10.34%) 0.776 1.00
1–25% positive cells 3 (25.0%) 12 (41.3%) 0.812 (0.084–7.817) 0.857
26–50% positive cells 4 (33.3%) 8 (27.6%) 1.406 (0.157–12.601) 0.76
Over 50% positive cells 4 (33.3%) 6 (20.7%) 1.726 (0.193–15.445) 0.626
bcl-2 0% positive cells 1 (8.3%) 10 (34.5%) 0.274 1.00
1–25% positive cells 9 (75.0%) 13 (44.9%) 5.396 (0.681–42.765) 0.111
26–50% positive cells 2 (16.7%) 4 (13.8%) 4.327 (0.392–47.775) 0.232
Over 50% positive cells 0 (0.0%) 2 (6.9%) NR
NR, no recurrence; HR, hazard ratio; CI, confidence interval
Table 3 Immunohistochemical expression of PCNA and p53 in the epithelial component of OKCs with hazard risks for recurrence
Recurrent cysts
(n = 12)
Non-recurrent cysts
(n = 29)
P value
(Mann-Whitney test)
Cox proportional
hazard model
Median
(range) [%]
Mean
(SD) [%]
Median
(range) [%]
Mean
(SD) [%]
HR (95% CI) P value
PCNA 24 (17.62–35) 27.25 (14.35) 19.5 (16–29) 23.07 (9.62) 0.282 1.039 (0.982–1.098) 0.185
p53 12 (9.75–14.25) 13.5 (7.29) 11 (5–16) 11.47 (6.96) 0.414 1.04 (0.958–1.129) 0.346
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current study, we found positive correlation between bcl-2 and
COX-2 which corroborates the conclusions of other authors [11,
35].We did not, however, reveal significant association between
bcl-2 immunopositivity and recurrence of OKC.
PCNA has been shown to be a useful marker for the prolif-
erating fraction of cells in various head and neck tumors [38]. By
employing PCNA staining, epithelial lining of OKC has been
demonstrated to have a comparable proliferative potential to that
of ameloblastoma [39]. High expression of PCNA in OKCmay
reflect the high level of cell proliferative activity in the lining
epitheliumwhich supported the outdated concept of the neoplas-
tic nature of this lesion [9, 40]. In the current study, it has been
demonstrated that there is a positive correlation between expres-
sion of PCNA and presence of cortical perforation which may
serve as a strong prognostic factor for OKC recurrence.
However, we have found no significant association between
PCNA immunopositivity and recurrence of OKC. To the best
of our knowledge, there are no other studies available which
assessed PCNA as a potential marker of OKC relapse, with
the exception of el Murtadi et al. [10] who discovered that mean
PCNA count in recurrent OKCs was significantly lower in com-
parisonwith that in de novo cases. They suggested that this trend
indicates that the stimulus for proliferation is maximum around
the time of occurrence of the primary cyst and does not appear to
be continuous throughout life as it decreases in intensity with
time [10]. It is difficult to compare the results of the study by el
Murtadi et al. [10] with ours, as we did not analyze primary
OKCs vs. recurrences of OKCs but all our cases were primary
which were subdivided into recurrent and non-recurrent cases.
Moreover, in contrast to the current study, el Murtadi et al. [10]
also included syndromic cases to their analysis.
Resu l t s o f some inves t iga t ions showed tha t
immunoexpression of p53 strongly correlateswith the recurrence
of various head and neck tumors [41]; however, the prognostic
value of p53 immunostaining in oral cancer has been disputed
[42]. With regard to OKC, only Razavi et al. [43] demonstrated
that evaluation of p53 expression at the time of diagnosis may be
useful for the prediction of recurrence. Other authors, including
Lombardi et al. [44], Gurgel et al. [45], andKuroyanagi et al. [8],
did not find statistically significant differences in expression of
p53 between recurrent and non-recurrent OKCs, and their results
are consistent with ours. These discrepancies may result from the
fact that OKC can show different clinical behaviors, which was
also pointed out by Razavi et al. [43].
Irrespective of the current non-neoplastic concept of OKC
pathobiology [2], from the clinical point of view, some OKC
cases show an indolent course typical for most of odontogenic
cysts, while others demonstrate aggressive behavior similar to
that of ameloblastoma. Thus, further research on larger num-
ber of cases which may allow to stratify these clinically dis-
tinct OKC cases is essential. In this material encompassing a
relat ively smal l number of cases, assessment of
immunoexpression of COX-2, bcl-2, PCNA, and p53 was
not useful to identify cyst with more aggressive phenotype
and higher tendency to relapse.
It can be concluded that some radiological features of spo-
radic OKCs, such as larger size, multilocularity, and evidence
of cortical perforation, may indicate higher risk of recurrence.
However, the significance of the association between these
radiographic characteristics of OKC and its tendency to re-
lapse requires confirmation in large-scale studies. We also
found that expression of PCNA significantly correlates with
the radiological presence of cortical perforation, and that there
is a significant positive correlation between immunopositivity
for COX-2 and bcl-2 and significant negative correlation be-
tween immunopositivity for COX-2 and age. Nevertheless,
Table 4 Clinicoradiological and histopathological characteristics of the recurrent cases of OKC
No. Age Sex Location
Relapse
period
(months)
Cyst
variant
Size of
lesion
(mm2)
Cortical
perforation
Inflammatory
score
Number of
daughter cysts
Epithelial
dysplasia
COX-
2
[grade]
bcl-2
[grade]
PCNA
[%]
p53
[%]
1 48 F A-Mn 24 UL 950 (+) 2 0 (−) 2 1 10.5 6
2 36 F P-Mn 36 UL 760 (−) 0 0 (−) 2 2 13 13
3 15 M P-Mn 72 ML 1148 (+) 0 0 (−) 3 1 23 11.5
4 19 M A-Mn 108 ML 950 (+) 1 0 (+) 2 1 24 18
5 36 M P-Mn 36 ML 594 (+) 0 0 (−) 3 1 13.5 11
6 67 M P-Mn 60 ML 1064 (+) 0 0 (−) 0 1 19 21
7 29 M P-Mn 72 UL 700 (−) 2 0 (−) 3 1 24 9
8 58 M A-Mx 24 UL 375 (+) 3 1 (−) 1 0 38 12.5
9 10 F A-Mx 24 UL 375 (+) 0 1 (−) 2 1 38 32
10 62 M A-Mn 24 ML 875 (−) 1 3 (−) 1 1 28 10
11 18 M A-Mn 18 ML 1350 (+) 0 0 (−) 3 2 62 5.5
12 70 M A-Mx 84 ML 759 (+) 1 0 (−) 1 1 34 12.5
A-Mn, anterior mandible; P-Mn, posterior mandible; A-Mx, anterior maxilla; UL, unilocular; ML, multilocular
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further investigation is still necessary to reveal the precise
molecular factors behind OKC recurrence.
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